401 related articles for article (PubMed ID: 30207440)
1. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
[TBL] [Abstract][Full Text] [Related]
2. Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.
Lenz SM; Collins JH; Ray NA; Hagge DA; Lahiri R; Adams LB
PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008583. PubMed ID: 32936818
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.
Ji B; Perani EG; Petinom C; Grosset JH
Antimicrob Agents Chemother; 1996 Feb; 40(2):393-9. PubMed ID: 8834886
[TBL] [Abstract][Full Text] [Related]
4. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Matsuoka M; Kashiwabara Y; Namisato M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of New Antibacterial Drugs and their Combinations in a Murine Model to Identify Short Duration Alternative Chemotherapy for Leprosy.
Arumugam S; Joseph P; Ponnaiya J; Richard J; Das M; Chaitanya VS; Ebenezer M
Indian J Lepr; 2016; 88(3):159-76. PubMed ID: 30207441
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
Consigny S; Bentoucha A; Bonnafous P; Grosset J; Ji B
Antimicrob Agents Chemother; 2000 Oct; 44(10):2919-21. PubMed ID: 10991891
[TBL] [Abstract][Full Text] [Related]
7. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
8. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Mane I; Cartel JL; Grosset JH
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
[TBL] [Abstract][Full Text] [Related]
9. Newer drugs in leprosy.
Grosset JH
Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
[TBL] [Abstract][Full Text] [Related]
10. Ofloxacin resistance in multibacillary new leprosy cases from Purulia, West Bengal: a threat to effective secondary line treatment for rifampicin-resistant leprosy cases.
Ahuja M; Singh I; Lavania M; Pathak VK; Darlong J; Turankar RP; Hembrom S; Singh SV; Sengupta U
J Glob Antimicrob Resist; 2022 Sep; 30():282-285. PubMed ID: 35717020
[TBL] [Abstract][Full Text] [Related]
11. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.
Ji B; Grosset J
Lepr Rev; 2000 Dec; 71 Suppl():S81-7. PubMed ID: 11201894
[TBL] [Abstract][Full Text] [Related]
12. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
Dhople AM; Ibanez MA
Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
[TBL] [Abstract][Full Text] [Related]
13. Single-dose treatment for paucibacillary leprosy; clinical problems and management.
Pai VV; Bulchand HO; Revankar CR; Ganapati R
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):310-2. PubMed ID: 10575414
[No Abstract] [Full Text] [Related]
14. Molecular detection of multidrug-resistant Mycobacterium leprae from Indian leprosy patients.
Lavania M; Singh I; Turankar RP; Ahuja M; Pathak V; Sengupta U; Das L; Kumar A; Darlong J; Nathan R; Maseey A
J Glob Antimicrob Resist; 2018 Mar; 12():214-219. PubMed ID: 29097343
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.
Cambau E; Saunderson P; Matsuoka M; Cole ST; Kai M; Suffys P; Rosa PS; Williams D; Gupta UD; Lavania M; Cardona-Castro N; Miyamoto Y; Hagge D; Srikantam A; Hongseng W; Indropo A; Vissa V; Johnson RC; Cauchoix B; Pannikar VK; Cooreman EAWD; Pemmaraju VRR; Gillini L;
Clin Microbiol Infect; 2018 Dec; 24(12):1305-1310. PubMed ID: 29496597
[TBL] [Abstract][Full Text] [Related]
16. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up.
Ganapati R; Revankar CR; Pai VV; Kingsley S
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):308-9. PubMed ID: 10575413
[No Abstract] [Full Text] [Related]
17. The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice.
Burgos J; de la Cruz E; Paredes R; Andaya CR; Gelber RH
Lepr Rev; 2011 Sep; 82(3):253-8. PubMed ID: 22125933
[TBL] [Abstract][Full Text] [Related]
18. Possible mode of emergence for drug-resistant leprosy is revealed by an analysis of samples from Mexico.
Matsuoka M; Suzuki Y; Garcia IE; Fafutis-Morris M; Vargas-González A; Carreño-Martinez C; Fukushima Y; Nakajima C
Jpn J Infect Dis; 2010 Nov; 63(6):412-6. PubMed ID: 21099091
[TBL] [Abstract][Full Text] [Related]
19. [New WHO recommendations for the treatment of leprosy].
Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754
[No Abstract] [Full Text] [Related]
20. Ofloxacin containing combined drug regimens in the treatment of multibacillary leprosy.
Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
Southeast Asian J Trop Med Public Health; 1997 Dec; 28(4):803-10. PubMed ID: 9656405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
